• Explore /
  • Poster
  • / A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).

Abstract Poster

Authors

Pamela Kunz

Pamela L. Kunz

Stanford University School of Medicine, Stanford, CA

Pamela L. Kunz , Paul J. Catalano , Halla Sayed Nimeiri , George A. Fisher , Teri A. Longacre , Iris Schrijver , Diane Lauren Reidy , Jonathan R. Strosberg , Peter J. O'Dwyer , Al Bowen Benson III

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT01824875

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS4145)

DOI

10.1200/jco.2015.33.15_suppl.tps4145

Abstract #

TPS4145

Poster Bd #

250b

Abstract Disclosures

Similar Posters

First Author: Eduardo Terán Brage Sr.

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.

Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.

First Author: Ali Fawaz

First Author: Xin Qu

First Author: Hiromichi Shirasu